An updated expert statement may provide new support for expanded use of PCSK9 inhibitor cholesterol drugs. Since their initial approval two years ago usage of the expensive new drugs (Repatha from Amgen and Praluent from Sanofi and Regeneron) has been severely limited due to strict restrictions on reimbursement. Lack of evidence showing long term benefits ...
Forthcoming expert guideline may upgrade PCSK9 inhibitors
By Larry Husten
26 Jul 2017